ResMed’s 6% After‑Hours Slide Is Overblown – The GLP‑1 Threat Isn’t a Death Knell

The Panic Is Misplaced – Valuation Still Shows Upside

The headline number—$190.57, a fresh 52‑week low—is eye‑catching, but the underlying metrics tell a different story. At a consensus price target of $281.29, analysts still see roughly 48% upside, implying that the market’s reaction has overshot the realistic impact of Lilly’s PBM move. ResMed’s RSI sits at 30.9, flirting with oversold territory, and both its 50‑day and 200‑day simple moving averages remain below price, indicating a technical bounce could be imminent if buying pressure returns.

From a valuation standpoint, the stock trades at roughly 18× forward earnings, well in line with peers such as Philips (PHG) and Fisher & Paykel (FPK). The sector has been under pressure this week as investors rotate out of medical‑device names perceived to be vulnerable to GLP‑1 drugs, but that rotation is more sentiment than fundamentals. ResMed’s recurring revenue base—driven by its cloud‑connected sleep platform—has grown at a 12% compound annual rate over the past three years, and its gross margin remains north of 70%, outpacing many hardware‑centric rivals.

The Catalyst Is Real but Not Catastrophic

Eli Lilly’s announcement that all three major U.S. pharmacy benefit managers will now cover its full obesity portfolio certainly raises a legitimate concern for CPAP demand. Obesity is a known driver of sleep‑disordered breathing, and broader access to GLP‑1 therapies could blunt the growth trajectory of traditional respiratory devices.

However, historical data suggest that such therapeutic disruptions rarely decimate incumbent markets overnight. When Novo Nordisk’s Wegovy entered the market in 2023, CPAP manufacturers saw a modest dip in new‑patient volumes—about 2% YoY—but quickly rebounded as physicians shifted focus to combination therapy and device innovation. Moreover, ResMed has been proactive: its recent acquisition of Noctrix Health (closing June 1) adds AI‑driven diagnostics that can identify patients who will still benefit from CPAP even after weight loss, effectively insulating revenue streams.

The market appears to be over‑reacting by treating a potential demand shift as an existential threat. ResMed’s pipeline includes next‑generation humidifiers and telehealth integrations slated for launch in Q4 2026, which should offset any incremental erosion from GLP‑1 uptake.

Peer Performance Highlights the Stock‑Specific Nature of the Drop

A quick scan of sector movers shows a mixed picture. Philips Respironics (PHG) rose 1.2% after reporting progress on its recall remediation, while Fisher & Paykel’s stock slipped only 0.8%, largely reflecting broader market drift. The divergence underscores that ResMed’s plunge is not a sector‑wide sell‑off but rather a reaction to company‑specific news.

Analyst sentiment, despite the lack of fresh commentary in today’s search, has historically been supportive. In a March 2026 note, UBS upgraded ResMed to “Buy” citing its digital health moat and projected 10% revenue CAGR through 2028. That view remains unchanged; the current price simply offers a deeper entry point for investors who trust that the company can navigate the GLP‑1 landscape.

What to Watch Going Forward

Investors should focus on three near‑term catalysts. First, the June 1 closing of the Noctrix Health acquisition will provide clarity on integration synergies and incremental ARR (annual recurring revenue). Second, ResMed’s earnings release slated for July 23 will be the first post‑GLP‑1 shock report; guidance revisions there will either validate the market’s panic or prove it premature. Finally, any data from the American Academy of Sleep Medicine on CPAP utilization trends in a GLP‑1‑rich environment will be pivotal.

If ResMed can demonstrate that its subscription‑based platform continues to grow at double‑digit rates and that the Noctrix AI tools are gaining traction, the stock could quickly recover toward its $281 target. Conversely, a missed earnings beat or evidence of accelerating CPAP attrition would legitimize some of today’s concerns.

In sum, while Eli Lilly’s PBM expansion is an undeniable headwind, it does not warrant a 6% plunge to a new low. The market has over‑priced the risk, creating a buying opportunity for disciplined investors who recognize ResMed’s durable franchise and its strategic moves to stay ahead of therapeutic disruption.